SCHEMBL694657

SCHEMBL694657

N#Cc1ccc(Oc2cc(Cl)cc(Cl)c2)c(S(=O)(=O)N2CCN(C(=O)c3ccccc3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MMP2 P08253 2/20 0.46
MMP13 P45452 1/20 0.46
CNR1 P21554 2/20 0.45
KCNA5 P22460 1/20 0.45
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALOX12 P18054 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TBXA2R P21731 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197149 0.94 MEN1 (0.49) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL694277 0.93 KMT2A (0.56) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL694471 0.93 MEN1 (0.49) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL694272 0.91 MEN1 (0.52) MEN1KMT2ALMNAPOLBCYP3A4
SCHEMBL693966 0.91 MEN1 (0.54) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL693369 0.90 MEN1 (0.47) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL693221 0.90 USP2 (0.50) MEN1KMT2AALDH1A1GAACYP3A4
SCHEMBL694390 0.90 KMT2A (0.46) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL12693460 0.90 KMT2A (0.50) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL694654 0.89 LMNA (0.52) MEN1KMT2AALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502921-B1 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS INC (US) 2015-05-20 EP disclosed
EP-2502921-B1 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS INC (US) 2015-05-20 EP disclosed
US-8658642-B2 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2014-02-25 US disclosed
US-20130217687-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2013-08-22 US disclosed
US-8420639-B2 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2013-04-16 US disclosed
EP-2502921-A1 Arylsulfonamide CCR3 antagonists Axikin Pharmaceuticals, Inc. (US) 2012-09-26 EP disclosed
EP-2502921-A1 Arylsulfonamide CCR3 antagonists Axikin Pharmaceuticals, Inc. (US) 2012-09-26 EP disclosed
EP-2421838-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS Axikin Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20100273795-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 US disclosed
WO-2010123960-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 WO disclosed
WO-2010123960-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273795-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 MEN1 4563/4885KMT2A 2688/4885ALDH1A1 2454/4885
US-20130217687-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 MEN1 4563/4885KMT2A 2688/4885ALDH1A1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.